Business
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data
Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN
About this update from Guardant Health, Inc.
[{"type":"text","content":"Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of Verana's regulatory-grade, therapeutic-specific EHR curated datasets from leading medical societies and academic and community medical centers and Guardant's clinicogenomic testing data to accelerate the development of new therapies and enhance on-going patient care.\n \n \n \n \n \n \n \nUsing the extensive datasets the collaboration provides, research scientists can more easily understand and further validate correlations between molecular biomarkers, treatment decisions and clinical outcomes. For example, from an urology perspective novel use cases of combining genomics data with NMIBC EHR curated data could enhance understanding the patient journey in risk refinement beyond stage/grade, lead to better treatment selection insights (i.e., who benefits from Bacillus Calmette-Guerin (BCG), the standard of care for most Non-muscle invasive bladder cancer (NMIBC) patients vs. who needs earlier escalation, and validate biomarker measures (e.g., Tumor Mutational Burden (TMB)) using real-world response and outcome endpoints. Ultimately, the combination provides greater insights into existing research data with comprehensive real-world data—including critical longitudinal serial testing information—needed to optimize drug development and accelerate programs that treat cancer across diverse patient populations.\"Clinicogenomic data empowers research scientists to test hypotheses by studying patient genomic profiles and real-world outcomes to guide the development of targeted therapies that can be used to personalize treatment for each cancer patient,\" said Sujay Jadhav, CEO of Verana Health. \"Connecting Guardant's data to Verana Health's in-depth, real-world oncology, and urology data assets will also allow researchers to anticipate treatment responses and accelerate drug development for existing and new population segme...